Detailed view
The full calculators behind the planner. The settings are shared, so anything changed here also changes the planner.
Who does the checks, clinician time by region and the national cost.
Delivery models and regional workforce capacity
›How the Workforce Lab works
Choose who does the skin checks. For every region, ATOF computes how much of each local workforce's clinical time the programme would take at the selected threshold, using NHWDS supply data for dermatologists, skin-cancer GPs, GPs and practice nurses, and the same risk-based demand as the rest of the tool. Every assumption, with its current value and source, is listed under “Assumptions and what they mean”.
Skin-cancer GPs, other GPs and practice nurses share the checks. Mix: Skin-cancer GP 30% · Other GP 40% · Practice nurse 30%
ResultAt a 2.0% threshold with checks every 5 years and the Shared primary care model, 87 of 88 regions can deliver within the 10% time cap; the programme would cost about $17M a year net and avert about 104 melanoma deaths over 10 years but lose more health to overdiagnosis, biopsies and excisions than that gains, so it is not cost-effective at any value of a QALY. At published PBS prices, earlier diagnosis avoids up to $50M of melanoma treatment over 10 years (188 fewer advanced-melanoma episodes), offsetting 26% of the programme's cost.
How certain?working out the range…Each simulation draws the uncertain inputs of the cost and health model at once: how many adults already have regular skin checks, how far checks lower thick melanomas and raise thin and in situ ones (Aitken 2010, Whiteman 2022), how often the adults in those studies were checked, whether a melanoma found earlier is found in situ or at stage I, how long a melanoma can be found before it surfaces, how long one that would never cause harm stays detectable and how often a check finds either, how much of the stage shift is real rather than lead time, overdiagnosis, survival, biopsies and excisions per check, treatment and check prices, and the health lost per death, per advanced melanoma, per overdiagnosis and per biopsy or excision. The settings you choose (threshold, who does the checks, how often, attendance, ages, the risk-assessment cost) are held fixed.
Compared with usual care (today's skin checks), for everyone above 2.0% risk (2,118,842 adults, of whom 1,059,421 attend). Price used: $84 per check on average for this delivery mix (GP $86, practice nurse $47; dermatologist referrals and tele-review add $9, at $186 per referral consult), plus $36 per check for follow-up biopsies, excisions and pathology. The regular checkers' own checks it replaces are priced at $86 (a GP check) plus $40 follow-up. Deterministic base case of the tool's cost-utility model (illustrative).
| Item | 10 years (discounted) | Per year (average) |
|---|---|---|
| A round of risk assessment every 10 years for every eligible adult aged 40 and over, at $5.00 per adult: the average cost per eligible adult of finding out who is above the threshold (invitation, questionnaire, follow-up), whether or not the adult responds (an assumption). One round in the 10-year programme. This is how the programme finds the people above the threshold.Risk assessment of adults 40+ | $64.7M | $6.5M |
| First-line checks for the adults above the threshold who attend, at the chosen interval: $75 per check on average for this delivery mix, before referrals. Checks are spread evenly over the programme.Programme skin checks | $128M | $15.8M |
| GP and practice-nurse checks referred to a dermatologist (5%, at $185.91 per referral consult).Dermatologist referrals and tele-review | $16.0M | $2.0M |
| Follow-up procedures after programme checks: a biopsy after 8.3% and an excision after 8.0% of GP checks (Goldsbury 2024), scaled by who does the check (dermatologist ×0.5, skin-cancer GP ×0.7, other GP ×1, practice nurse ×1). After photography + AI, 50% of the flagged adults see a GP in person and have a procedure. $36.37 per check for this mix.Biopsies, excisions and pathology | $62.5M | $7.7M |
| 37% of the adults who attend already have a skin check every year. Programme checks replace those checks one for one (100% replaced): 78,397 checks a year, at $86.34 each plus $39.97 follow-up. Adults below the threshold keep today's checks.Regular checkers' own checks replaced (−) | −$80.3M | −$9.9M |
| Finding melanomas earlier means fewer reach an advanced stage. These lines are the change in melanoma treatment cost, over the lifetime of the melanomas found during the 10 years.Treatment avoided by earlier diagnosis: | −$50.0M | −$6.7M |
| Systemic treatment of stage IV melanoma and of relapses after an earlier-stage diagnosis: $265k per episode (immunotherapy or targeted therapy, infusions, a later line of therapy, imaging and serious side-effects), excluding end-of-life care. Earlier diagnosis means fewer melanomas progress.Advanced melanoma (immunotherapy) episodes | −$37.4M | −$5.0M |
| Treatment of each melanoma at the stage it is found: surgery, sentinel node biopsy, imaging and, for stage III, adjuvant immunotherapy. Earlier stages cost less: stage I $3k against stage III $74k per patient.Stage-at-diagnosis treatment | −$8.6M | −$1.1M |
| Care in the last year of life for each melanoma death: $62k (hospital and medical care; medicines are excluded because they are in the episode cost). Fewer deaths, less end-of-life care.End-of-life care | −$4.1M | −$643k |
| Treatment of the extra melanomas found that would never have caused harm (overdiagnosis): in situ and stage I melanomas, each at the price of its stage ($883 and $3k). 10,784 extra over the programme. Always counted, also in the budget view: the programme itself creates this cost. The cost model has its own overdiagnosis estimates (see Assumptions); the overdiagnosis switch on the decision curves does not change it.Extra treatment of overdiagnosed melanomas (+) | $14.0M | $1.7M |
| Whole-body checks also find keratinocyte cancers (basal and squamous cell carcinoma), which are then removed: after 3.4 of every 100 GP skin checks (Goldsbury 2024), at about $426 each (2026 MBS fees, excision with pathology and a results consultation). Only the extra checks count: programme checks less the regular checkers' own checks they replace. Most of these cancers would have been treated later anyway, so by default only the cost of treating them 1 to 3 years earlier is counted, about 14% of the full cost. The full cost is an upper bound. Counted here: cost of treating earlier, in the budget view too.Keratinocyte cancers treated (+) | $2.2M | $271k |
| The sum of the counted lines: the 10-year incremental cost behind the cost per QALY, and the net cost per year.Net | $157M | $17.3M |
National totals over the 10-year programme, against usual care, undiscounted. Like every national count in the Lab they scale with the average 10-year melanoma risk setting (now 1.25%).Advanced-melanoma episodes avoided over 10 years: 188; melanoma deaths averted: 104.
The average patient contribution on each check, referral and follow-up procedure (2026 MBS fees and Medicare statistics: most GP skin checks are bulk-billed, about $12 per check on average), less what regular checkers no longer pay for their own checks that the programme replaces. It is part of the health-system total above and left out of the government view.Patients' out-of-pocket costs: about $2M a year more than today.
Itemised unit costs · Immunotherapy era (2026) · health system perspective · edit prices, hourly rates, procedures and consumables
| Rows with a box are editable: check prices (or the GP and dermatologist hourly rates that set them), the referral consult, nurse time and photography inputs, procedure prices and consumables, and the risk-assessment cost per adult. Type a value to rerun the whole Lab with it. Treatment rows are read-only: they show the unit costs the model uses for this era and perspective. Tags: Published = from a published schedule or study (MBS, PBS, IHACPA, journal costings); Assumption = no direct source, a modelling choice; Edited = you changed it. “Reset to default costs” returns every edited value to its default.Item and reference | Value | Status |
|---|---|---|
| Programme checks (per check) | ||
GP / skin-cancer GP check MBS 23 (72%) / 36 (28%) + bulk-billing incentive 75870, MBS 1 Jul 2026; benefit + average patient contribution | Published | |
GP time, per hour Sets the GP check price: rate × 15 min per check ÷ 60. The default is the MBS fee expressed per hour. | /h | Published |
Dermatologist check MBS 105 subsequent attendance (MBS 104 initial attendance for referrals), MBS 1 Jul 2026; benefit + average patient contribution | Published | |
Dermatologist time, per hour Sets the dermatologist check price: rate × 15 min per check ÷ 60. The default is the MBS fee expressed per hour. | /h | Published |
Practice nurse check No MBS item; bottom-up practice-nurse time + practice overhead (assumptions): 25 min at $75.00/h loaded + 50% overhead; both perspectives | Assumption | |
Photography + AI check No MBS item; bottom-up nurse capture time + AI licence + device amortisation (assumptions): 30 min capture (+ 50% overhead) + $20.00 AI licence + $25.00 device per scan; tele-review priced separately | Assumption | |
Dermatologist referral consult MBS 104 (initial attendance); benefit + average patient contribution; after 5% of GP and nurse checks | Published | |
Tele-review of flagged images 5 ÷ 15 min of a dermatologist check; 10% of photography checks flagged | $47.32 | Assumption |
| Nurse time and photography (build the nurse and photography check prices) | ||
Registered nurse, per hour (fully loaded) Assumption (panel $70-90/h). A nurse check takes 25 min and photography capture 30 min. A check price typed above takes precedence. | /h | Assumption |
Practice overhead on nurse time Assumption: share added to nurse time for rooms, equipment and administration | % | Assumption |
AI licence, per scan Assumption (range $0-50) | Assumption | |
Imaging device, per scan (amortised) Assumption (range $10-60) | Assumption | |
| Finding the programme population | ||
Risk assessment per adult Every adult 40+, one round every 10 years: the average cost per eligible adult of finding out who is above the threshold (invitation, questionnaire, follow-up), whether or not the adult responds; range $0-15 | Assumption | |
| Follow-up after a check | ||
Biopsy + pathology MBS 30071 + 72816 + 73926; benefit + average patient contribution; after 8.3% of GP checks (Goldsbury 2024) | Published | |
Excision + pathology MBS 31366/31381 + pathology; benefit + average patient contribution; after 8.0% of GP checks (Goldsbury 2024) | Published | |
Results consult MBS 23, one per biopsy or excision; benefit + average patient contribution | Assumption | |
Procedure consumables (suture kit, dressings) Added to every biopsy, excision and keratinocyte-cancer excision. Default $0: taken as covered by the MBS fee and patient contribution; range $0-60 | Assumption | |
Keratinocyte cancer excision + pathology Excision (incl. flap share) + pathology; benefit + average patient contribution; after 3.4% of checks (Goldsbury 2024), plus a results consult | Published | |
Follow-up per check, this delivery mix GP-check rates × provider factor: dermatologist ×0.5, skin-cancer GP ×0.7, other GP ×1, practice nurse ×1. Photography + AI: 50% of the flagged adults have a GP visit and a procedure | $36.37 | Published |
| Melanoma treatment (per patient) | ||
In situ, at diagnosis Excision, pathology, follow-up (Gordon 2022) | $883.17 | Published |
Stage I, at diagnosis Elliott 2017 local treatment + sentinel node biopsy for 20% (assumption) | $3,383 | Published |
Stage II, at diagnosis Gordon 2022 (IB/II first year) + stage IIC imaging | $9,307 | Published |
Stage III, at diagnosis Surgery (Watts 2017), BRAF test, imaging, oncologist consults (MBS 110/116), adjuvant immunotherapy (PBS; 65% uptake of eligible IIIB-D, assumption) | $73,535 | Published |
Advanced melanoma episode (excl. end-of-life) Sum of the components below | $264,802 | Published |
First-line systemic therapy (PBS drugs) PBS 1 Oct 2026 public-hospital prices; PBAC regimen mix and mean durations; 85% receive systemic therapy (assumption) | $190,667 | Published |
Infusion day admissions IHACPA NEP 2026-27 same-day infusion admission | $21,134 | Published |
Subsequent line of therapy (mostly drugs; discounted) 40% × $90,000 (CheckMate 067: 36-50% had later therapy) | $36,000 | Assumption |
Imaging, oncology consults, brain MRI Itemised estimate (CT, consults, brain MRI, BRAF test) | $9,000 | Assumption |
Serious immune side-effects, radiotherapy Itemised estimate (grade 3-4 side-effect admissions, radiotherapy) | $8,000 | Assumption |
End-of-life care, per melanoma death Goldsbury 2026 terminal phase, distant disease, excluding PBS medicines ($48,751, 2019 AUD), indexed | $61,865 | Published |
2026 AUD. MBS 1 Jul 2026 fees and PBS 1 Oct 2026 prices; hospital episodes and infusions at public-hospital prices (IHACPA NEP 2026-27) in both perspectives; the health-system view adds average out-of-pocket costs for office-based care. A check is assumed to find a melanoma equally often whoever performs it. Health effects come from the cost-utility model (2026 reference case: what checks do calibrated to Aitken 2010 and Whiteman 2022; 10-year melanoma survival by stage, calibrated; lifetime consequences of melanomas found during the programme; 5% discounting; stage shift 75% real); see Methods and the Value per person page.
ResultAt published PBS prices, earlier diagnosis avoids up to $50M of melanoma treatment over 10 years (188 fewer advanced-melanoma episodes), offsetting 26% of the programme's cost.
Assumptions and what they mean
Current values: they change as you move the controls. Each item is tagged with where it comes from.
- Measurednational data (NHWDS, ABS, Cancer Atlas)
- Publishedtaken from a published study or guideline
- Derivedcomputed from published prices or data combined with stated assumptions
- Estimatedmodelled from data (workforce analyses of NHWDS and Medicare data, or the risk model)
- Assumptionno direct source; a modelling choice
- Leveryou set it with the controls
Who is checked (demand)
- Eligible adults12.93M
MeasuredAdults aged 40 and over in the 88 SA4 regions, from ABS population estimates at 30 June 2024.
- Risk threshold2.0%
LeverPredicted 10-year melanoma risk above which an adult is offered programme checks. Shared with the rest of the tool.
- Risk toolQSkin MP16, AUC 0.69
PublishedDiscrimination of the selected risk tool (AUC). Source: 45 and Up external validation (Reyes-Marcelino et al., JAMA Dermatology 2026): Whiteman et al. 2025, 0.69 (0.68-0.71).
- Above the threshold16.4% (2.12M)
EstimatedAdults whose predicted risk exceeds the threshold, from a binormal risk distribution with this AUC and each region's average risk. Assumes the tool is equally well calibrated in every region.
- Average 10-year melanoma risk1.25%
AssumptionNational average among eligible adults; a shared setting in the decision-curve section (default 1.25%).
- Regional risk×0.40 to ×1.83
MeasuredEach region's average risk = national average × its invasive melanoma SIR (Cancer Atlas 2.0, 2010–19), adjusted for its age mix within 40+.
- Check intervalevery 5 yr
LeverChecks a year = adults above the threshold who attend ÷ interval (plus the higher-risk tier, if on).
- Guidelines and who is coveredscenarios
PublishedThe risk tools predict a first melanoma in people who have never had one (QSkin MP16: Whiteman 2025); survivors follow separate guideline surveillance, not modelled here. The RACGP Red Book advises checks at least yearly at high risk and 6-monthly at very high risk, with no numeric risk cut-off, so the intervals here are modelling scenarios (2-yearly as in Germany's programme; 5-yearly as in UK modelling, Wilson 2018).
- Attendance50%
Assumption50% of the adults above the threshold attend their checks. The rest carry on as today: no programme checks, no change in cost or benefit. Every adult is still risk-assessed. Drop-out between rounds is not modelled. The default, 50%, is close to established programmes: BreastScreen Australia reaches about 50% of eligible women and the National Bowel Cancer Screening Program about 41% of the people it invites (AIHW).
- Keratinocyte cancers3.4 per 100 extra checks
PublishedBasal and squamous cell carcinomas removed after extra checks (Goldsbury 2024 (keratinocyte cancer excised within 3 months after 3.4% of GP skin checks); 2026 MBS fees), at the cost of an excision with pathology and a results consultation; $271k a year at these settings (cost of treating them earlier counted). Most would have been treated later anyway, so by default only the cost of treating them earlier is counted (14% of the full cost). The cost panel can count the full cost, an upper bound, or leave them out.
- Patients' out-of-pocket costs+$2M a year
DerivedAverage patient contributions at 2026 MBS fees (most GP skin checks are bulk-billed; about $12 per GP check and 12.5% of the government benefit on procedures), on programme checks, referrals and follow-up, less the regular checkers' own checks that the programme replaces. Included in the health-system view, left out of the government view.
- Adults below the thresholdas today
AssumptionThey keep today's checks: 37% of them have a whole-body skin check every year and the rest have none, so they add no cost and no change in health. The setting can make the regular checkers have fewer or more.
- Risk assessment$5 per adult
AssumptionOne round every 10 years for every eligible adult: one round in the 10-year programme. The amount is the average cost per eligible adult of finding out who is above the threshold (invitation, questionnaire, follow-up), whether or not the adult responds. Nationally $6M a year, averaged over the programme. Costed, but not counted in clinician time, which starts at the skin check. Basis: Assumption $5 (0-15) per eligible adult, one round per 10-year programme.
Clinician time (supply)
- Minutes per check15 min
LeverClinician time for one first-line check by a GP or dermatologist, and for a dermatologist referral consult. A nurse check takes 25 minutes and a photography session 30 at this setting (25 and 30 when a GP check takes 15; assumptions).
- Procedures after checks5.7 min per GP check
AssumptionThe biopsies, excisions and results consultations that follow checks take clinician time: a biopsy 20 minutes, an excision 30 and a results consultation 10 (assumptions), at the rates under “Follow-up after a check”. After a dermatologist's or GP's check the time is theirs; after a nurse check or a flagged photograph it is a GP's.
- Hours per full-time clinician1,840 h/yr
Assumption40 clinical hours a week (the NHWDS full-time definition for doctors) × 46 weeks (Department of Health GP FTE convention). Converts hours to full-time clinicians. A practice-nurse FTE is 38 hours a week in the NHWDS, so it supplies 1,748 hours a year.
- Dermatologists535 FTE
MeasuredNHWDS 2024: 657 dermatologists averaging 33 clinical hours a week, equal to 535 full-time clinicians (clinical hours ÷ 40; teaching, research and admin time excluded). Each is counted in the SA4 of their main job. 46 of 88 regions publish only a band; together they are set to the published national total minus the other regions.
- GPs27,457 FTE
MeasuredNHWDS 2024 GP clinical hours ÷ 40 by main-job SA4, split into skin-cancer GPs and other GPs.
- Skin-cancer GPs3,764 FTE
EstimatedGP clinical FTE × the state's share of GP time in skin-cancer work (Medicare calibration, posterior median 12.8%–14.8% by state).
- Practice nurses10,616 FTE
MeasuredNHWDS 2024 nurses whose main job area is primary care: all of them, not only those trained in skin checks. In future years the number per person aged 40+ is held at its 2024 level.
- Workforce yeartoday (2024)
LeverToday uses 2024 supply. Future years scale dermatologist and GP supply by the projected clinical FTE per person aged 40+ (median of the workforce projection from NHWDS 2013–2024), which allows for population growth.
- Regions are self-containedassumed
AssumptionClinicians serve only the SA4 of their main job (second jobs and travel ignored), except pooled dermatologist review.
- Max share of any workforce's time10%
LeverA region can deliver if no local workforce needs more than this share of its clinical hours: 10% = up to 1 in 10 clinical hours. A policy choice, not measured spare capacity.
- Referred to a dermatologist5%
LeverShare of GP and practice-nurse checks passed on for a dermatologist consult as long as a check.
- AI flags for tele-review10%
LeverShare of photography + AI checks whose images the AI flags. It sets the dermatologists' tele-review load and how many GP visits and procedures follow photography.
- Tele-review time5 min
LeverDermatologist minutes per flagged image set.
- Dermatologist review fromIn-region
LeverReferrals and tele-reviews done by the region's own dermatologists, or shared across the state's or Australia's (teledermatology). First-line dermatologist checks stay local.
- Photography + AI50% of flags lead to a procedure
AssumptionA practice nurse captures the images (30 minutes a session at this setting) and AI triage uses no clinician time. Then every flagged image set is tele-reviewed by a dermatologist, and 50% of the flagged adults then see a GP in person and have a biopsy or excision (assumption, range 30% to 90%).
Price of a check (2026 AUD)
- GP / skin-cancer GP check$86
PublishedMBS 23 (72%) / 36 (28%) + bulk-billing incentive 75870, MBS 1 Jul 2026; Medicare benefit plus the average patient contribution.
- Dermatologist check$142
PublishedMBS 105 subsequent attendance (MBS 104 initial attendance for referrals), MBS 1 Jul 2026; Medicare benefit plus the average patient contribution.
- Practice nurse check$47
AssumptionNo MBS item; bottom-up practice-nurse time + practice overhead (assumptions); same in both perspectives.
- Photography + AI check$101
AssumptionNo MBS item; bottom-up nurse capture time + AI licence + device amortisation (assumptions); same in both perspectives.
- Referrals and tele-review+$9 per check
AssumptionA referral is priced as a dermatologist referral consult ($186); a tele-review as review minutes ÷ check minutes of a dermatologist check ($47).
- Average for this mix$84 per check
EstimatedProvider costs weighted by the delivery mix, plus referral and tele-review costs.
- Follow-up after a check+$36 per check
PublishedBiopsy after 8.3% and excision after 8.0% of GP checks (Goldsbury 2024): $40 per GP check, each priced at its MBS items with pathology and a results consult. Scaled by who does the check (next item) to the cost for this delivery mix.
- Follow-up by who checks×0.5 to ×1
AssumptionBiopsy and excision rates relative to a GP check: dermatologist ×0.5, skin-cancer GP ×0.7, other GP ×1, practice nurse ×1. Photography + AI is not on this scale: 50% of the flagged adults have a GP visit and a procedure. Informed by Goldsbury 2024 per-check rates; Petty 2020 NNT; Rosendahl 2012; Soyer 2025.
- Price year2026 AUD
EstimatedMBS 1 Jul 2026 fees, PBS 1 Oct 2026 prices and IHACPA NEP 2026-27 are used as published; older costs indexed to 2026 (factors: 2013 ×1.39, 2017 ×1.32, 2019 ×1.27, 2020 ×1.24, 2021 ×1.22, 2024 ×1.08). Source: AIHW Total Health Price Index, Health expenditure Australia 2023-24, Table 39a (https://www.aihw.gov.au/reports/health-welfare-expenditure/health-expenditure-australia-2023-24/data); FY-ending-year keys, 2025-26 extrapolated at 4.04%/yr; 2013 mapped to 2013-14 (2012-13 not in table).
Usual care and what the programme replaces
- Usual care37% checked every year
PublishedToday's skin checks, in two groups: regular checkers (37% of adults, 1 whole-body check a year) and adults with no regular checks. National Sun Protection Survey 2016-17: 37% of adults 45-69 had a whole-body skin check in the past 12 months (Reyes-Marcelino 2021); 43% in the 45 and Up Study 2020 (Reyes-Marcelino 2026). Each check is priced as a GP check with its follow-up: $86 plus $40.
- Replaced by the programme100%
AssumptionProgramme checks replace a regular checker's own checks one for one: 78,397 checks a year now ($10M). A regular checker who attends is therefore found no earlier unless programme checks are more frequent than their own, and the health gain comes from adults who are not checked today. 37% of the adults who attend are taken to be regular checkers (37% of all adults are). Adults below the threshold keep today's checks.
Treatment costs (earlier diagnosis)Finding melanomas earlier changes what their treatment costs. These lines are counted when "Count treatment costs avoided by earlier diagnosis" is ticked in the cost panel (now counted). Survival is used whether or not they are counted.
- Treatment eraImmunotherapy era (2026)
Lever2026 prices (MBS 1 Jul 2026, PBS 1 Oct 2026, IHACPA NEP 2026-27) with survival under modern treatment of advanced melanoma (immunotherapy and targeted therapy). Costs and survival change together.
- Survival basis10-yr, calibrated (k = 0.76)
Derived10-year melanoma-specific survival by stage at detection, for melanomas that would progress, used as the lifetime chance of dying of melanoma. Now: I 94%, II 81%, III 72%, IV 45%. Built from published pre-immunotherapy survival per diagnosed melanoma (I 93%, II 70%, III 55%, IV 12%), with every stage's fatality lowered by 18% for modern treatment of advanced melanoma. Each stage's fatality is divided by the share of that stage's diagnoses that are progressive, because an overdiagnosed melanoma cannot cause death. Then one factor k scales every stage's fatality so that melanoma deaths per invasive melanoma diagnosed under usual care equal 8.3%, the Australian ratio of melanoma deaths to invasive diagnoses. The same k applies in both eras. Sources: 10-yr MSS: AJCC7/Balch 2009 approx (pre-immunotherapy); AJCC8 10-yr (published upper-bound reference, not used as a model option); AIHW ACD 2017-21 (stage II proxy); Stage IV 10-yr 0.12 -> 0.28 (SEER distant 2016-22; AU 2011; CheckMate 067 10-yr, trial upper bound) (before calibration; calibrated advanced-disease 10-yr survival ≈ 45%, consistent with AIHW deaths and PBAC first-line patient numbers and with CheckMate 067 10-yr melanoma-specific survival 44–52%); AIHW melanoma deaths (~1,450) / incidence (~17,400); PBAC ~2,139 first-line advanced patients/yr.
- P(death | advanced melanoma)55%
DerivedChance that advanced melanoma (stage IV at diagnosis, or a later relapse) ends in melanoma death: the calibrated stage IV 10-year fatality. Advanced-disease episodes = melanoma deaths ÷ this, so each death averted avoids 1.81 episodes. Stage IV episodes start at diagnosis, relapses 2 years later.
- Advanced melanoma episode$265k
DerivedPer episode, excluding end-of-life care: first-line systemic therapy (PBS drugs) $191k; infusion day admissions $21k; subsequent line of therapy (mostly drugs; discounted) $36k; imaging, oncology consults, brain MRI $9k; serious immune side-effects, radiotherapy $8k. Spread over 3 years from the episode start ($163k / $92k / $10k). Sources: Episode component costs (imaging, consults, toxicity care: assumptions); IHACPA NEP 2026-27 infusion $1,792; PBAC PSD nivolumab+relatlimab (market, mean durations); Minister's release (940 pts/yr); PBS Schedule 1 Oct 2026, public-hospital DPMA.
- Adjuvant immunotherapy (stage III)65% uptake
AssumptionOffered after surgery for stage IIIB–D (78% of stage III); uptake 65% (assumption, range 45%–85%); real-world course of 231 days; mix nivolumab 77%, pembrolizumab 10%, dabrafenib + trametinib 13%. Expected $48k per stage III patient, in the stage III cost. No survival credit is given for adjuvant therapy. Source: DUSC Sept 2022 adjuvant nivolumab review (mix, 231-day median); AJCC8 IIIB-D share 78%.
- Treatment at the stage found$3k to $74k
DerivedPer patient: in situ $883, stage I $3k, stage II $9k, stage III $74k (including expected adjuvant therapy); stage IV is costed as an advanced episode. The health-system view adds patient out-of-pocket costs for office-based care (12.5% of the government cost, an assumption). Sources: Gordon 2022 (IJERPH 19:3178); Elliott 2017; Watts 2017 hospital costs; MBS 30311/61553/110/116.
- End-of-life care$62k per death
PublishedCare in the last year of life for each melanoma death, 5 years after diagnosis: Goldsbury 2026 terminal phase, distant, excl. PBS medicines: $72,761 x 67% (hospital 55% + MBS 12%), S1 File Table E (2019 AUD), indexed to 2026. Medicines are left out because they are in the episode cost.
- Drug discount0%
LeverOff published PBS prices of melanoma drugs (immunotherapy and targeted therapy), not off pharmacy or preparation fees. 0% = published price, an upper bound (the usual convention), since rebates are confidential. Source: PBS Schedule 1 Oct 2026, public-hospital DPMA.
- PerspectiveHealth system
LeverHealth system = government plus the average patient contribution for office-based care; government = Commonwealth and state (Medicare benefits, the PBS, public hospitals). Hospital episodes and infusions are at public-hospital prices in both. Source: MBS 1 Jul 2026 fees; Medicare statistics 2025-26 average patient contributions.
- Not modelledconservative omissions
AssumptionOperable regional relapses after a stage I–II diagnosis (surgery plus adjuvant therapy) are not costed, so treatment savings are understated. Attendance is a setting (50% by default). Keratinocyte cancers found at checks are costed in their own line, not here.
Health economics
- Time horizon10-yr programme
AssumptionMelanomas found during the programme carry their lifetime consequences: treatment at the stage found, advanced-disease episodes, end-of-life care and life-years lost.
- Discounting5% a year
PublishedCosts and QALYs discounted to programme start (Australian reference case). Programme checks are spread evenly over the programme, on the same clock as the health events they lead to. The yearly net cost is not discounted.
- Melanomas found by a check30% at this interval
AssumptionShare of progressive melanomas found by a check before they would surface on their own: 30% with 5-yearly checks, 55% with 2-yearly, 72% with yearly and 84% with 6-monthly checks. It follows from a mean detectable period of 2 years and a 80% chance that one check finds a detectable melanoma (both assumptions). In proportion to this share, stage II or later melanomas fall.
- Overdiagnosed melanomas found by a check72% at this interval
AssumptionA melanoma that would never have caused harm does not surface on its own, so it stays detectable for longer: 10 years on average, an assumption that no study has measured. A check therefore finds more of them: 72% with 5-yearly checks, 87% with 2-yearly, 93% with yearly and 96% with 6-monthly checks. Overdiagnosed in situ and stage I melanomas rise in proportion to this share, so checks at long intervals bring most of the overdiagnosis but a smaller part of the benefit.
- Effect of regular checksstage II+ ×0.74, stage I ×1.29, in situ ×1.45
PublishedThe sizes come from Australian studies of adults whose skin had been examined against adults whose skin had not. The examined adults, taken to have 0.55 checks a year, had stage II or later melanomas 0.74 times as often, stage I melanomas 1.29 times as often and in situ melanomas 1.45 times as often. Aitken 2010 (Int J Cancer 126:450-8): whole-body clinical skin examination in the 3 years before diagnosis; melanomas 1.5 mm or thicker (two thickness groups pooled), odds ratio 0.74 (0.61-0.90). Examined adults taken to have 0.55 checks a year (Janda 2004: 11% examined in 12 months, 20% in 3 years). Aitken 2010: odds ratio 1.38 (1.22-1.56) for melanomas 0.75 mm or thinner and 0.93 (0.79-1.10) for 0.76-1.49 mm; combined 1.29 for melanomas under 1.5 mm (those 0.75 mm or thinner taken as 80%). Whiteman 2022 (Br J Dermatol 187:515-22), QSkin: in situ melanoma 1.45 (1.09-1.92) times as common in adults whose skin was examined by a doctor in the previous 3 years. The extra stage I and in situ melanomas are counted as overdiagnosis.
- Where earlier-found melanomas are found50% in situ
AssumptionA melanoma that a check finds before it reaches stage II is found in situ or at stage I. No data say which, so the share found in situ is an assumption. A melanoma found in situ cannot cause death in the model; one found at stage I still can.
- Stage-shift realisation75%
AssumptionShare of the survival gain implied by earlier stage counted as real, allowing for lead-time bias; the advanced-disease episodes avoided scale with it. Not yet calibrated to Policy1-Melanoma natural history.
- Overdiagnosisin situ 73%, stage I 28%
DerivedOverdiagnosed share of the melanomas diagnosed under usual care, by stage. Lindsay 2024 estimated it for melanoma in situ and for thin invasive (stage IA) melanoma; applying the stage IA figure to all stage I is an ATOF extension, not a finding of the paper. With Australian diagnoses by stage (Australian Cancer Atlas 2010-2019 (persons): 165,641 in situ and 134,543 invasive melanomas; invasive melanomas by the national registry stage mix), about 50% of all melanomas diagnosed today are overdiagnosed. Checks add overdiagnosed in situ and stage I melanomas: 10,784 over the programme at these settings, about 104 for each melanoma death averted (the number depends on the check interval). Each costs the treatment of its stage and some quality of life, with no survival gain.
- Melanoma deaths7.3 QALYs lost each
DerivedQALYs lost per melanoma death, discounted to the time of death, which is counted 5 years after detection (range 6.4 to 8.6; 8.5 discounted life-years before quality weighting). AIHW melanoma deaths by age and sex (2023) × ABS life tables 2022–2024, weighted by Australian EQ-5D-5L population norms (McCaffrey 2016). The mean age at death from melanoma is 75.4. The chance of death by stage is under “Survival basis”.
- Harm of an overdiagnosis0.05 QALY lost each
DerivedQuality of life lost by a person treated for a melanoma that would never have harmed them (range 0.02 to 0.26), on top of the cost of the treatment. Stage I/II utility at surgery and over the following year (Tran 2018 meta-analysis) against the Australian population norm; no loss after the first year.
- Harm of a biopsy or excision0.0011 QALY lost each
AssumptionQuality of life lost with each biopsy or excision that follows a check (range 0.0005 to 0.003). At these settings there are 18,650 more procedures a year than today. Utility 0.971 after a benign excision (Chen 2004, in Watts 2017), taken for two weeks (assumption).
- Living with advanced melanoma0.3 QALY lost per episode
AssumptionQuality of life lost while living with advanced melanoma, before death or lasting remission (range 0.15 to 0.6). Life lost after a death is counted separately. Assumption 0.3 QALY (0.15-0.6): stage IV on treatment 0.58 (Tromme 2014 / Watts 2017) against the population norm, about one year.
- Same accuracy whoever checkskey simplification
AssumptionA check is assumed to find a melanoma equally often whoever performs it, so melanoma deaths averted are the same across delivery models. QALYs differ, because the delivery models lead to different numbers of biopsies and excisions.
- Value of a QALY$50k
LeverAustralia has no official threshold. Reference values: $28k (Edney 2018, opportunity cost), $50k (commonly cited) and $65k, close to the cost per QALY estimated in MSAC 1699 (National Lung Cancer Screening Program), a screening precedent rather than a melanoma assessment.
- Uncertaintypoint estimates
AssumptionResults in this section are a deterministic base case; no uncertainty intervals are shown here.
In this delivery model dermatologists only review referrals and flagged images: about 30 hours a year here. The region has dermatologist supply published only as a band (1-<2 FTE; the tool uses a value inside the band, scaled to the national total), so that is 1% of local dermatologist time. These reviews need not be local: set "Dermatologist review from" to state to share them across the state's dermatologists (teledermatology).
- Dermatologist-ledno
- Skin-cancer GP-ledyes
- Shared primary careyes
- Nurse photography + AIyes
Dermatologist supply here is published only as a band (1-<2 FTE) under small-cell disclosure rules; shares use a value inside the band, scaled so that all such regions add up to the published national total.
| Delivery model | Regions that can deliver | Eligible adults covered | Dermatologist time (national) | Busiest local workforce (median SA4) | Lowest feasible threshold (median SA4) | Net cost per year | Cost per QALY |
|---|---|---|---|---|---|---|---|
| Dermatologist-led | 40 / 88 | 55% | 6.4% | 12.2% | 2.3% | $26M | $5M |
| Skin-cancer GP-led | 87 / 88 | 98% | 0.3% | 1.3% | 0.5% | $18M | no net gain |
| Shared primary care | 87 / 88 | 98% | 0.3% | 0.6% | 0.5% | $17M | no net gain |
| Nurse photography + AI | 88 / 88 | 100% | 0.2% | 0.6% | 0.5% | $18M | $2M |
›Data sources
Data. Dermatologist and GP clinical FTE: NHWDS 2024 clinical hours/40 by main-job SA4. Skin-cancer GPs: GP FTE × each state's skin-cancer share of GP time (Medicare calibration). Practice nurses: NHWDS 2024, nurses whose main job area is primary care (not projected). Demand: people above the threshold under the selected model (external AUC, invasive SIR × 40+ age mix), divided by the check interval. Workforce years ahead use the per-capita workforce projection (NHWDS 2013–2024). Levers (minutes, referral, AI flag, tele-review minutes, time cap) are scenario assumptions, not estimates. Clinician time includes the biopsies, excisions and results consultations that follow checks. Regions are treated as self-contained; clinicians are counted where their main job is. Full list with current values: “Assumptions and what they mean”.